Do statins reduce the incidence of stroke in familial hypercholesterolemia?

References

• Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic Bases of Inherited Diseases (Seventh Edition). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill Book Co, NY, USA, 1981–2030 (1995).
   Google Scholar
• Hoffman U, Dirisamer A, Heher S, Kostner K, Widham K, Neuntefl T. Relation of flow-mediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol.90, 70–73 (2002).
   PubMedGoogle Scholar
• Tonstad S, Joakimsen O, Stensland-Bugge E et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscle. Thromb. Vasc. Biol.16, 984–991 (1996).
   PubMed Web of Science ®Google Scholar
• Mabuchi H, Koizumi J, Shimizu M, Takeda R. Development of coronary heart disease in familial hypercholesterolemia. Circulation79, 225–232 (1989).
   PubMed Web of Science ®Google Scholar
• Simon Broome Steering Committee. Steering committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis142, 105–112 (1999).
   PubMed Web of Science ®Google Scholar
• Neil A, Cooper J, Betteridge J et al. Reductions in all-cause, cancer and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J.29, 2583–2584 (2008).
   PubMedGoogle Scholar
• Hutter CM, Austin MA, Humphries SE. Familial hypercholesterolemia, peripheral disease, and stroke: a HuGE minireview. Am. J. Epidemiol.160, 430–435 (2004).
   PubMed Web of Science ®Google Scholar
• Kaste M, Koivisto P. Risk of brain infarction in familial hypercholesterolemia. Stroke19, 1097–1100 (1988).
   PubMedGoogle Scholar
• Tomlinson B, Lan IW, Hamilton-Craig I. Screening for familial hypercholesterolemia. Funding is difficult to obtain but screening can be international (letter). BMJ322, 1061 (2001).
   PubMedGoogle Scholar
• Meschia JF. Familial hypercholesterolemia: stroke and the broader perspective. Stroke34, 26–27 (2003).
   Google Scholar
• Kaste M. Every day is world stroke day. Act now, be a stroke champion and a torchbearer! Stroke41, 2449–2450 (2010).
   PubMedGoogle Scholar
• O’Donnell MJ, Xavier D, Liu L et al.; INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case–control study. Lancet376, 112–123 (2010).
   PubMed Web of Science ®Google Scholar
• Brown MS, Kovanen PT, Goldstein JL, Regulation of plasma cholesterol by lipoprotein receptors. Science212, 628–635 (1981).
   PubMed Web of Science ®Google Scholar
• Mardual M, Carrié A, Sassolas A et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum. Mutat.31, E1811–E1824 (2010).
   Google Scholar
• Hachinski V, Donnan GA, Gorelick PB et al. Stroke: working toward a prioritized world agenda. Cerebrovasc. Dis.30, 127–147 (2010).
   PubMed Web of Science ®Google Scholar
• Buchwald H, Varco RL. Ileal bypass in patients with hypercholesterolemia and atherosclerosis. JAMA70, 290–296 (1984).
   Google Scholar
• Mabuchi H, Miyamoto S, Ueda K et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis61, 1–6 (1986).
   PubMed Web of Science ®Google Scholar
• Huxley RR, Hawkins MH, Humphries SE, Karpe F, Neil HAW; for the Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Stroke34, 22–27 (2003).
   PubMedGoogle Scholar
• Pantonini L, Garcia J. Pathogenesis of leukoasiaosis: a review. Stroke28, 652–659 (1997).
   PubMedGoogle Scholar
• Gerdes VE, Kwa VI, ten Cate H, Brabdjes DP, Buller HR, Stam J. Cerebral white matter lesions predict both ischemic strokes and myocardial infarctions in patients with established atherosclerotic disease. Atherosclerosis186, 166–172 (2006).
   PubMed Web of Science ®Google Scholar
• Soljanlahti S, Autti T, Lauerma K et al. Familial hypercholesterolemia patients treated with statins at no increased risk for intracranial vascular lesions despite increased cholesterol burden and extracranial atherosclerosis. Stroke36, 1572–1574 (2005).
   PubMedGoogle Scholar
• Schmitz SA, O’Regan DP, Fitzpatrick J et al. White matter brain lesions in midlife familial hypercholesterolemic patients at 3-Tesla magnetic resonance imaging. Acta Radiol.49, 184–189 (2008).
   PubMed Web of Science ®Google Scholar
• Soljanlahti S, Raininko R, Hyttinen L et al. Statin-treated familial hypercholesterolemia patients with coronary heart disease and pronounced atherosclerosis do not have more brain lesions than healthy controls in later middle age. Acta Radiol.48, 894–899 (2007).
   PubMed Web of Science ®Google Scholar
• Vuorio AF, Turtola H, Piilahti KM, Repo P, Kanninen T, Kontula K. Familial hypercholesterolemia in the Finnish North Karelia. A molecular, clinical, and genealogical study. Arterioscler. Thromb. Vasc. Biol.17, 3127–3138 (1997).
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt R, Nordestgaard BG, Schnohr P, Tybjærg-Hansen A. Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. Eur. Heart J.25, 943–951 (2004).
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt R, Arlien-Søborg P, Thorsen S, Jensen HK, Vorstrup S. LDL receptor mutations and ApoB mutations are not risk factors for ischemic cerebrovascular disease of young, but lipids and liporpoteins are. Eur. J. Neurol.6, 691–696 (1999).
   PubMedGoogle Scholar
• Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ341, 3666–3675 (2010).
   PubMed Web of Science ®Google Scholar
• Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. Stroke40, 2068–2072 (2009).
   PubMed Web of Science ®Google Scholar
• Imamura T, Doi Y, Arima H et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hsiyama Study. Stroke40, 382–388 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson CA, Hutchison A, Dennis MS et al. Differering risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy? Stroke41, 624–629 (2010).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet376, 1670–1681 (2010).
   PubMed Web of Science ®Google Scholar
• De Caterina R, Scarano M, Marfisi RM et al. Cholesterol-lowering interventions and stroke. Insights from a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol.55, 198–211 (2010).
   PubMed Web of Science ®Google Scholar
• Gagné C, Moorjani S, Brun D, Toussaint M, Lupien P-J. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischemic heart disease in men and women. Atherosclerosis34, 13–24 (1979).
   PubMed Web of Science ®Google Scholar